PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial

BACKGROUND: PF-06649751 is a novel, oral, non-catechol-based, D1/D5 dopamine receptor partial agonist under investigation for the treatment of motor symptoms associated with Parkinson’s disease. METHODS: A 15-week, phase II, double-blind, placebo-controlled clinical trial was conducted to assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Riesenberg, Robert, Werth, John, Zhang, Yao, Duvvuri, Sridhar, Gray, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066585/
https://www.ncbi.nlm.nih.gov/pubmed/32201505
http://dx.doi.org/10.1177/1756286420911296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066585/
https://www.ncbi.nlm.nih.gov/pubmed/32201505
http://dx.doi.org/10.1177/1756286420911296

Ejemplares similares